Adjuvant intravesical treatment with a standardized mistletoe extract to prevent recurrence of superficial urinary bladder cancer

Anticancer Research

Volumn 25, Issue 6 C, 2005, Pages 4733-4736

  Elsässer Beile, Ursula ^a   Leiber, Christian ^a   Wetterauer, Ulrich ^a   Bühler, Patrick ^a   Wolf, Philipp ^a   Lucht, Martin ^a   Mengs, Ulrich ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b Madaus AG   (Germany)

Author keywords

Adjuvant intravesical treatment; Mistletoe extract; Mistletoe lectin; Superficial bladder cancer

Indexed keywords

BCG VACCINE; LECTIN; VISCUM ALBUM EXTRACT;

ADULT; AGED; ARTICLE; BIOPSY TECHNIQUE; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTOSCOPY; CYTODIAGNOSIS; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENCE RISK; SIDE EFFECT; STANDARDIZATION; TRANSURETHRAL RESECTION; WORLD HEALTH ORGANIZATION;

ADMINISTRATION, INTRAVESICAL; ADULT; AGED; AGED, 80 AND OVER; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MALE; MIDDLE AGED; MISTLETOE; NEOPLASM RECURRENCE, LOCAL; PHYTOTHERAPY; PLANT EXTRACTS; PROSPECTIVE STUDIES; URINARY BLADDER NEOPLASMS;

EID: 28444498775     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Kurth KH, Bouffioux C, Sylvester R, van der Meijden AP, Oosterlinck W and Brausi M: Treatment of superficial bladder tumors: achievements and needs. The EORTC Genitourinary Group. Eur Urol 37 Suppl 3: 1-9, 2000.
2. Amling CL: Diagnosis and management of superficial bladder cancer. Curr Probl Cancer 25: 219-278, 2001.
3. Rawls WH, Lamm DL, Lowe BA, Crawford ED, Sarosdy MF, Montie JE, Grossman HB and Scardino PT: Fatal sepsis following intravesical bacillus Calmette-Guerin administration for bladder cancer. J Urol 144: 1328-1330, 1990.
4. Deresiewicz RL, Stone RM and Aster JC: Fatal disseminated mycobacterial infection following intravesical bacillus Calmette-Guerin. J Urol 144: 1331-1333; discussion 1333-1334, 1990.
5. Lamm DL, van der Meijden PM, Morales A, Brosman SA, Catalona WJ, Herr HW, Soloway MS, Steg A and Debruyne FM: Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol 147: 596-600, 1992.
6. Ernst E, Schmidt K and Steuer-Vogt MK: Mistletoe for cancer? A systematic review of randomised clinical trials. Int J Cancer 107: 262-267, 2003.
7. Kienle GS, Berrino F, Bussing A, Portalupi E, Rosenzweig S and Kiene H: Mistletoe in cancer - a systematic review on controlled clinical trials. Eur J Med Res 8: 109-119, 2003.
8. Stauder H and Kreuser ED: Mistletoe extracts standardised in terms of mistletoe lectins (ML I) in oncology: current state of clinical research. Onkologie 25: 374-380, 2002.
9. Hajto T, Hostanska K and Gabius HJ: Modulatory potency of the {beta}-galactoside-specific lectin from mistletoe extract (Iscador) on the host defense system in vivo in rabbits and patients. Cancer Res 49: 4803-4808, 1989.
10. Hajto T, Hostanska K, Frei K, Rordorf C and Gabius HJ: Increased secretion of tumor necrosis factor α, interleukin 1, and interleukin 6 by human mononuclear cells exposed to β-galactoside-specific lectin from clinically applied mistletoe extract. Cancer Res 50: 3322-3326, 1990.
11. Gabius HJ, Walzel H, Joshi SS, Kruip J, Kojima S, Gerke V, Kratzin H and Gabius S: The immunomodulatory beta-galactoside-specific lectin from mistletoe: partial sequence analysis, cell and tissue binding, and impact on intracellular biosignalling of monocytic leukemia cells. Anticancer Res 12: 669-675, 1992.
12. Ribereau-Gayon G, Dumont S, Muller C, Jung ML, Poindron P and Anton R: Mistletoe lectins I, II and III induce the production of cytokines by cultured human monocytes. Cancer Lett 109: 33-38, 1996.
13. Mengs U, Gothel D and Leng-Peschlow E: Mistletoe extracts standardized to mistletoe lectins in oncology: review on current status of preclinical research. Anticancer Res 22: 1399-1407, 2002.
14. Mengs U, Schwarz T, Bulitta M and Weber K: Antitumoral effects of an intravesically applied aqueous mistletoe extract on urinary bladder carcinoma MB49 in mice. Anticancer Res 20: 3565-3568, 2000.
15. Vang OPL, K and Bog-Hansen TC: A New Quantitative and Highly Specific Assay for Lectinbinding Activity, 5. Berlin - New York: W. de Gruyter, pp. 637-644, 1986.
16. Elsasser-Beile U, Ruhnau T, Freudenberg N, Wetterauer U and Mengs U: Antitumoral effect of recombinant mistletoe lectin on chemically induced urinary bladder carcinogenesis in a rat model. Cancer 91: 998-1004, 2001.